High-sensitivity cardiac troponin i and T methods for the early detection of myocardial injury in patients on chemotherapy

Aldo Clerico, Daniela Maria Cardinale, Martina Zaninotto, Nadia Aspromonte, Maria Teresa Sandri, Claudio Passino, Marco Migliardi, Marco Perrone, Antonio Fortunato, Andrea Padoan, Tommaso Trenti, Sergio Bernardini, Laura Sciacovelli, Furio Colivicchi, Domenico Gabrielli, Mario Plebani

Research output: Contribution to journalArticlepeer-review


Important advances achieved in pharmacological cancer treatment have led progressively to a reduction in mortality from many forms of cancer, and increasing numbers of previously incurable patients can now hope to become cancer-free. Yet, to achieve these improved outcomes a high price has been paid in terms of untoward side effects associated with treatment, cardio-toxicity in particular. Several recent studies have reported that cardiac troponin assay using high-sensitivity methods (hs-cTn) can enable the early detection of myocardial injury related to chemotherapy or abuse of drugs that are potentially cardiotoxic. Several authors have recently suggested that changes in hs-cTn values enable the early diagnosis of cardiac injury from chemotherapy, thus potentially benefitting cancer patients with increased troponin values by initiating early cardioprotective therapy. However, large randomised clinical trials are needed in order to evaluate the cost/benefit ratio of standardised protocols for the early detection of cardiotoxicity using the hs-cTn assay in patients treated with chemotherapy.

Original languageEnglish
Pages (from-to)513-521
Number of pages9
JournalClinical Chemistry and Laboratory Medicine
Issue number3
Publication statusPublished - Feb 1 2021


  • cardiac troponin
  • cardio-toxicity
  • chemotherapy
  • high-sensitivity methods
  • myocardial injury

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'High-sensitivity cardiac troponin i and T methods for the early detection of myocardial injury in patients on chemotherapy'. Together they form a unique fingerprint.

Cite this